Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome ResistanceJames A. McCubrey, Alberto M. Martelli|Oncotarget|2012Cited by 315
Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades Which Alter Therapy Response.James A. McCubrey, Alberto M. Martelli|Oncotarget|2012Cited by 303
Multifaceted roles of GSK-3 and Wnt/β-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic interventionJames A. McCubrey, Alberto M. Martelli|Leukemia|2013Cited by 249
Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemiaCarolina Simioni, Alberto M. Martelli|Leukemia|2012Cited by 87
Therapeutic potential of targeting sphingosine kinases and sphingosine 1-phosphate in hematological malignanciesCamilla Evangelisti, Alberto M. Martelli|Leukemia|2016Cited by 42